



In Vitro Activity of Lefamulin against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CAP): 2015 SENTRY Data from Europe

Paukner, Susanne ¹; Sader, Helio S. ²; Streit, Jennifer ²; Flamm, Robert K. ²; Gelone, Steven P. ¹; ¹, Nabriva Therapeutics AG, Vienna, Austria; ², JMI Laboratories, North Liberty, IA, USA

Nabriva Therapeutics AG
Vienna, Austria
and King of Prussia, PA, USA
www.nabriva.com
susanne.paukner@nabriva.com

INTRODUCTION & PURPOSE

Background: Lefamulin is the first semi-synthetic pleuromutilin antibiotic for IV and oral use in humans. It is currently in Phase 3 trials for the treatment of CAP in adults. Lefamulin effectively and selectively inhibits bacterial translation by binding to the peptidyl transferase center (PTC) at two sites. It interacts via four H-bonds and other interactions resulting in an "induced fit" whereby nucleotides in the PTC shift and further tighten the binding pocket around lefamulin (Figure 1).^{1,2}

Lefamulin has demonstrated potent *in vitro* activity against a variety of pathogens that cause skin and soft tissue infections and respiratory tract infections caused by Gram positive, fastidious Gram-negative, and atypical bacteria including *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *Legionella pneumophila*.^{3,4} Lefamulin showed similar efficacy to IV vancomycin in a clinical Phase 2 trial in patients with acute bacterial skin and skin structure infections.⁵ Furthermore, lefamulin has been well tolerated in phase 1 and phase 2 trials.

CAP is the number one infectious diseases cause of death worldwide and emerging resistance complicates its treatment.⁶ This study investigated the activity of lefamulin and comparators against a contemporary set of bacterial respiratory pathogens collected in Europe.




Figure 1. Lefamulin in the PTC

METHODS

Unique patients' isolates ($n=1040$) were collected in Europe (19 countries, 36 sites) from patients with respiratory tract infections (87.5%), blood stream infections (8.4%) and other infections (4.1%). Only one isolate per patient infection episode was included in surveillance.

Lefamulin and comparators were tested by CLSI broth microdilution methods and susceptibility was determined using the EUCAST (2017) breakpoints.^{7,8} QC reference organisms were tested concurrently for lefamulin and comparator agents.

RESULTS

- Lefamulin displayed potent antibacterial activity against this collection of respiratory pathogens with all 1040 isolates inhibited at concentrations of ≤ 2 mg/L (Table 1).
- Lefamulin was the most active compound against *S. pneumoniae* (MIC_{50/90} of 0.06/0.12 mg/L) with only 3 isolates inhibited by a lefamulin concentration of ≥ 0.5 μ g/mL
 - S. pneumoniae* isolates were susceptible to levofloxacin (98.6%), whereas 27.6%, 24.6% and 13.2% of isolates were resistant to macrolides, tetracycline, and ceftriaxone, respectively.

Table 1. Susceptibility of CABP pathogens against lefamulin and comparators

Organism (N)	MIC ₅₀	MIC ₉₀	MIC ₉₉	Range	% Susceptible ^a	% Intermediate ^a	% Resistant ^b
<i>S. pneumoniae</i> (710)							
Lefamulin	0.06	0.12	0.25	≤ 0.008 to 1			
Amoxicillin-clavulanic acid	≤ 0.03	2	>4	≤ 0.03 to >4			
Azithromycin	0.06	>4	>4	≤ 0.03 to >4	72.1	0.3	27.6
Ceftaroline	≤ 0.008	0.12	0.25	≤ 0.008 to 0.25	100.0		0.0
Ceftriaxone	0.03	1	2	≤ 0.015 to >2	86.8	12.5	0.7
Clindamycin	≤ 0.12	>1	>1	≤ 0.12 to >1	81.0		19.0
Erythromycin	0.03	>2	>2	≤ 0.015 to >2	72.3	0.1	27.6
Imipenem	≤ 0.015	0.25	0.5	≤ 0.015 to 0.5	100.0		0.0
Levofloxacin	1	1	>4	≤ 0.12 to >4	98.6		1.4
Penicillin	≤ 0.06	2	4	≤ 0.06 to 8	68.6	27.3	4.1 ^b
Tetracycline	0.25	>4	>4	≤ 0.12 to >4	74.8	0.6	24.6
<i>H. influenzae</i> (170)							
Lefamulin	0.5	1	2	≤ 0.12 to 2			
Amoxicillin-clavulanic acid	0.5	2	4	≤ 0.12 to 8	97.6		2.4
Ampicillin	0.25	8	>8	0.12 to >8	84.7		15.3 ^c
Azithromycin	0.5	1	2	0.12 to 2	1.2	98.8	0.0
Ceftriaxone	≤ 0.015	≤ 0.015	0.06	≤ 0.015 to 0.06	100.0		0.0
Clarithromycin	4	8	16	1 to 16	2.4	97.6	0.0
Levofloxacin	≤ 0.015	≤ 0.015	0.5	≤ 0.015 to 0.5	98.2		1.8
Tetracycline	0.5	0.5	0.5	≤ 0.12 to >16	99.4	0.0	0.6
Trimethoprim-sulfamethoxazole	0.06	>4	>4	≤ 0.03 to >4	74.7	2.9	22.4
<i>M. catarrhalis</i> (160)							
Lefamulin	0.06	0.12	0.12	≤ 0.008 to 0.12			
Amoxicillin-clavulanic acid	0.12	0.25	0.25	≤ 0.03 to 0.25	100.0		0.0
Azithromycin	0.015	0.03	0.06	0.002 to 0.06	100.0	0.0	0.0
Ceftriaxone	0.25	0.5	0.5	≤ 0.015 to 1	100.0	0.0	0.0
Erythromycin	0.12	0.12	0.5	≤ 0.015 to 1	98.8	0.6	0.6
Levofloxacin	0.03	0.06	0.06	≤ 0.015 to 0.5	100.0		0.0
Tetracycline	0.12	0.25	0.5	≤ 0.03 to 0.5	100.0	0.0	0.0

^a Criteria as published by EUCAST [2017]

^b Non-meningitis breakpoints applied for penicillin

^c β -lactamase positive, reported as resistant for penicillins without inhibitors

RESULTS (con't)

- Lefamulin's activity was not affected by resistance to other antibiotic classes.
 - MIC_{50/90} of lefamulin against penicillin non-susceptible *S. pneumoniae* ($n=223$, non-meningitis breakpoint of >0.06 μ g/mL) were 0.06/0.12 μ g/mL
 - 100% of *S. pneumoniae* resistant to penicillin ($n=29$, breakpoint >2 μ g/mL) were inhibited by lefamulin concentrations of ≤ 0.12 μ g/mL;
 - PRSP showed high resistance rates to macrolides (93.1%), tetracycline (89.7%), amoxicillin-clavulanic acid (62.1%) and trimethoprim-sulfamethoxazole (96.6%) whereas PRSP were largely susceptible to levofloxacin (82.8%), tigecycline (100%) and vancomycin (100%).
 - 98.5% of macrolide-resistant *S. pneumoniae* ($n=196$) were inhibited by ≤ 0.25 μ g/mL lefamulin (MIC_{50/90} 0.06/0.12 μ g/mL, range 0.008-1 μ g/mL)
- Against the fastidious respiratory pathogens, lefamulin showed potent activity and was not affected by β -lactamase production.
 - H. influenzae*, MIC_{50/90} of 0.5/1 mg/L, including 12.9% of β -lactamase producing strains
 - M. catarrhalis*, MIC_{50/90} of 0.06/0.12 mg/L

CONCLUSIONS

- Lefamulin demonstrated potent *in vitro* activity against a contemporary collection of respiratory pathogens from Europe.
- Lefamulin was active regardless of resistance phenotype to the other antibiotic classes including macrolides, β -lactams, tetracyclines or fluoroquinolones.
- The lefamulin activity against this contemporary collection is consistent with results obtained from previous studies including a variety of *S. pneumoniae* serotypes.⁹
- These data support the continued clinical development of lefamulin for the treatment of respiratory tract infections, including CAP.

REFERENCES

- Eyal, Z., et al., *Sci Rep* 6, 39004 (2016)
- Prince, W. T, et al. *AAC* 57(5), 2087-2094 (2013)
- Paukner, S. and Riedl, R. Cold Spring Harbor Laboratory Perspectives, *Antibiotics and Antibiotic Resistance* (2016)
- Prina, E., et al. *Lancet* 386(9998), 1097-1108 (2015)
- Waites, K. B., et al. *AAC* 61(2)(2017)
- CLSI, *M100*(2017)
- EUCAST. *Breakpoint tables for interpretation of MICs and zone diameters V. 7.0* (2017)
- Mendes, R. E., et al. *AAC* 60(7), 4407-4411 (2016)